Standing ovation for Gilead as it boasts perfect efficacy in HIV PReP trial
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
The UNAIDS executive director has called upon Gilead Sciences to make its ‘miracle’ drug lenacapavir for human immunodeficiency virus (HIV)…
Researchers will present data from a ‘first-of-its-kind HIV cure’ stem cell transplant at the upcoming AIDS 2024 Conference. Experts will…
On 4 July 2024, the people of the UK took to the polls and made their voice heard, voting for…
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
An AI database that utilises real-world data (RWD) could help sponsors decide where to next investigate glucagon-like peptide-1 receptor agonists…
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
AC Immune is looking ahead to the second part of its Phase II Parkinson’s disease (PD) vaccine trial. The Swiss…
Pharma and biotechs have shared concerns about working with large CROs, saying that the ‘one-stop shop’ model is no longer…
Cancer Research UK (CRUK) is soon to move away from its UK-centric model as it is in conversation with other…